ScreenerHero

BSLN Basilea Pharmaceutica AG

SWX · CH · Healthcare · Biotechnology · basilea.com
66.00CHF-1.20%Mkt Cap: 933.43M $P/E: 16.46

Basilea Pharmaceutica AG is a Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections. The company offers Cresemba (isavuconazole), an intrav…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$127.54BUSDP/E 29.3
MRNA
Moderna, Inc.
$81.13BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$74.79BUSDP/E 18.0
ARGX
argenx SE
$57.11BUSDP/E 34.8
ARGX
argenx SE
$55.24BUSDP/E 36.1
RVMD
Revolution Medicines, Inc.
$44.51BUSD
UCB
UCB SA
$41.63BUSDP/E 17.7
ONC
BeOne Medicines AG
$41.14BUSDP/E 64.7
RPRX
Royalty Pharma plc
$32.74BUSDP/E 30.1
ALNY
Alnylam Pharmaceuticals, Inc.
$29.42BUSDP/E 37.1
ROIV
Roivant Sciences Ltd.
$25.84BUSD
BNTX
BioNTech SE
$24.53BUSD
GMAB
Genmab A/S
$24.01BUSDP/E 30.3
INCY
Incyte Corporation
$23.13BUSDP/E 14.5
INSM
Insmed Incorporated
$22.67BUSD
GMAB
Genmab A/S
$21.61BUSDP/E 29.3
JAZZ
Jazz Pharmaceuticals plc
$15.32BUSDP/E 16.2
ASND
Ascendis Pharma A/S
$15.01BUSDP/E 17.5
EXEL
Exelixis, Inc.
$14.58BUSDP/E 18.6
SMMT
Summit Therapeutics Inc.
$13.78BUSD

Key Statistics

Company
Market Cap933.43M USD
Enterprise Value843.33M USD
Revenue (TTM)282.38M USD
Gross Profit220.34M USD
Net Income (TTM)45.93M USD
Revenue/Share20.11 CHF
Last Price66.00 CHF
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees200
CountryCH
SectorHealthcare
IndustryBiotechnology
ISINCH0011432447
Valuation
P/E (Trailing)16.46
P/E (Forward)14.57
PEG-0.08
EV/EBITDA12.13
EV/Revenue2.99
P/S3.35
P/B5.10
EPS (TTM)4.01
EPS (Forward)4.58
52W Range
44.7083% of range70.50
52W High70.50 CHF
52W Low44.70 CHF
Profitability
Gross Margin83.08%
Oper. Margin26.90%
EBITDA Margin24.62%
Profit Margin17.32%
ROE31.45%
ROA14.27%
Growth
Revenue Growth14.50%
Earnings Growth64.40%
Cash Flow & Leverage
Operating CF70.86M USD
CapEx (TTM)3.27M USD
FCF Margin15.19%
FCF Yield4.59%
Net Debt-102.27M USD
Net Debt/EBITDA-1.47
Balance Sheet
Debt/Equity0.70
Current Ratio6.60
Quick Ratio5.81
Book Value/Sh13.09 CHF
Cash/Share13.95 CHF
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 CHF
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div DateApr 11, 2013
Pay Date—
Analyst Consensus
Rating—
Target (Mean)107.78 CHF
Upside (mean)+63.3%
Target Range75.00 CHF – 126.10 CHF
75.00+63.3% to mean126.10
# Analysts4
Ownership
Shares Out.12.39M
Float11.31M
Insiders0.62%
Institutions30.41%
Technical
SMA 5061.53 (+7.3%)
SMA 20055.60 (+18.7%)
Beta0.43
S&P 52W Chg14.58%
Avg Vol (30d)40.07K
Avg Vol (10d)27.37K
Technical Indicators
RSI (14)50.5
MACD1.5077
MACD Signal2.1147
MACD Hist.-0.6070
BB Upper70.85 CHF
BB Middle67.36 CHF
BB Lower63.86 CHF
BB Width10.37%
ATR (14)1.786 CHF
Vol Ratio (20d)0.52x